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Abstract: Members of the human kallikrein-related peptidase (KLK) family, including KLK5, have been reported to 
play an important role in ovarian cancer progression. In the present study, we assessed KLK5 protein expression in 
ovarian cancer tissues by immunohistochemistry (IHC) and ELISA, and analyzed its association with clinicopatho-
logic parameters and disease outcome in 95 patients with advanced ovarian cancer FIGO stage III/IV. KLK5 immu-
noexpression was evaluated in ovarian cancer tissue microarrays by IHC using a manual semiquantitative scoring 
system. KLK5 antigen levels were determined in ovarian cancer tumour tissue extracts by ELISA. KLK5 protein is 
expressed in ovarian cancer tissue by stromal and tumor cells. Mean KLK5 immunoscore values in tumor cells 
(KLK5-Tc; 5.7, range 0 to 12) were higher compared to stromal cells (KLK5-Sc; 1.2, range 0 to 9) but the correlation 
between KLK5-Tc and KLK5-Sc was rather low (rs = 0.34, P < 0.05). No significant associations of clinicopathological 
parameters with KLK5-Tc, KLK5-Sc, the combined overall score KLK5-Tc+Sc, or ELISA (KLK5-E) expression values 
were determined, except for KLK5-E protein expression with advanced age and high nuclear grade (G3). In uni-
variate Cox regression analysis, elevated expression levels of KLK5-Sc are significantly linked with both prolonged 
overall survival (OS) (hazard ratio [HR] = 0.6, P = 0.046) and progression-free survival (PFS) (HR = 0.54, P = 0.032) 
of advanced ovarian cancer patients. KLK5-Tc and KLK5-Tc+Sc scores as well as the KLK5-E values were not associ-
ated with patients’ outcome. In multivariable analysis, KLK5-Sc expression was found to be statistically significant 
for PFS. Patients with elevated KLK5-Sc had a two-fold lower risk of disease recurrence (HR = 0.53, P = 0.037) as 
compared to patients with low KLK5-Sc. For KLK5-Sc and OS, a trend towards statistical significance was observed 
(HR = 0.62, P = 0.077). These results indicate that KLK5 overexpression by stromal cells (KLK5-Sc) may be a posi-
tive modulator lowering aggressiveness of ovarian cancer. 
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Introduction 
Ovarian cancer is the leading gynecologic 
malignancy in women resulting in death in the 
western world. Early ovarian cancer usually pre-
sents no obvious symptoms, therefore, the 
poor prognosis of this disorder is often the 
result of late diagnosis associated with untime-
ly disease recurrence [1]. Currently, there is no 
suitable screening test for women at average 
risk of ovarian cancer which has been recog-
nized to be helpful in the early detection of ovar-
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ian cancer; at best, the combination of a thor-
ough pelvic exam, transvaginal ultrasound, and 
testing for the blood tumor marker CA125 is 
offered to women who are considered high-risk 
ovarian cancer patients, or to women who have 
persistent, unexplained symptoms [1]. Thus, 
until now, no sufficiently accurate screening 
tests or biomarkers are available to tailor can-
cer therapy to the individual patient. 
In this respect, it is worth to mention that sev-
eral of the fifteen kallikrein-related peptidases 
(KLK) family members have been reported to 
contribute to ovarian cancer progression and 
metastasis (reviewed in [2, 3]). While e.g. KLK4, 
KLK6, and KLK15 are associated with poor 
clinical outcome of ovarian cancer patients, 
KLK9 and KLK14 are linked with a favorable 
course of the disease. For some KLKs (KLK7, 8, 
10, 11, and KLK13) the clinical relevance is not 
clear yet. Previous findings made obvious that-
either at the protein or gene level-elevated 
KLK5 concentrations present in ovarian cancer 
tumor tissue are associated with advanced dis-
ease stage as well as shorter disease-free and 
overall survival ([4-7]). 
Like the other KLKs, KLK5 is a secreted serine 
protease. In healthy individuals, it is mainly pre-
sent in the skin (often co-expressed with KLK7), 
but is also found in the breast, cervix, esopha-
gus, heart, salivary gland, testis, thyroid, and 
vagina [8]. In the skin, KLK5 is involved in des-
quamation, probably acting as a physiological 
activator of KLK7 [9]. Interestingly, in advanced 
serous ovarian cancer tissue, a concordant 
higher expression of both KLK5 and KLK7 was 
observed when compared to normal or benign 
ovarian tissue [10].
In the present study, we assessed KLK5 pro-
tein expression in tumor tissues by two immu-
noenzymometric assays, immunohistochemis-
try (IHC) and ELISA, in a cohort of advanced 
ovarian cancer patients, employing well-char-
acterized antibodies to KLK5. Localization and 
expression levels of KLK5 in formalin-fixed par-
affin-embedded sections were determined sep-
arately for tumor cells and stromal cells. The 
findings were correlated with clinical and histo-
morphological parameters but also with clinical 
outcome of the ovarian cancer patients.
Patients, material and methods
Patients 
Ninety-five patients afflicted with advanced 
ovarian cancer (FIGO stage III/IV), treated 
between 1990 and 1999, were enrolled in the 
present retrospective study conducted at the 
Department of Obstetrics and Gynecology, 
Klinikum rechts der Isar, Technische Universität 
München, Germany. The study was approved by 
the local Ethics Committee. Median patients’ 
age at time of surgery was 57 years (range 
20-85 years). All patients initially underwent 
the standard stage-related primary radical 
Table 1. Association between clinical and histomorphological characteristics of advanced ovarian 
cancer patients FIGO III/IV and tumor biological factors
Clinicopathological parameters No. of patients 
KLK5-Tc KLK5-Sc KLK5-Tc+Sc KLK5-E
low/higha low/highb low/highb low/high
Total 95 58/34 58/32 48/42 62/33
Age P = 0.886 P = 0.418 P = 0.931 P = 0.009
    ≤ 60 years 56 35/20 33/21 29/25 22/34
    > 60 years 39 23/14 25/11 19/17 26/13
Nuclear grade P = 0.712 P = 0.791 P = 0.924 P = 0.015
    G1 + G2 27 15/10 16/8 13/11 19/8
    G3 68 43/24 42/24 35/31 29/39
Residual tumor mass P = 0.477 P = 0.411 P = 0.489 P = 0.833
    0 cm 39 27/12 22/15 22/15 20/19
    > 0 cm 53 31/19 34/16 26/24 26/27
Ascitic fluid volume P = 0.127 P = 0.514 P = 0.232 P = 0.928
    < 500 ml 53 37/16 31/20 30/21 27/26
    ≥ 500 ml 40 20/17 25/12 17/20 20/20
Chi2 test (cut-off point: median); No. of cases an = 92; bn = 90.
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debulking surgery. Thirty-nine patients (41.1%) 
were optimally debulked with complete removal 
of macroscopically visible tumor manifesta-
tions. Following surgery, all of the patients 
received adjuvant treatment according to con-
sensus recommendations at that time, includ-
ing platinum-based chemotherapy. None of the 
patients received neoadjuvant therapy before 
primary surgery. Median time of follow-up was 
40 and 23 months for overall survival (OS) and 
progression-free survival (PFS), respectively 
(range 1 to 244 months after primary tumor 
resection, for both). Clinical and histomorpho-
logical factors documented at the time of sur-
gery included nuclear grade, presence of resid-
ual tumor mass (defined as largest intra-
abdominal tumor diameter left at the end of 
surgery) and ascitic fluid volume (estimated 
preoperatively by vaginal ultrasound) (Table 1). 
During follow-up, 65 (68%) of the patients 
relapsed; 77 (81%) died.
Tissue preparation, microarray construction, 
and immunohistochemistry
Formalin-fixed, paraffin-embedded ovarian tis-
sue specimens were retrieved from the archives 
of the Institute of Pathology of the Technis- 
che Universität München, Munich, Germany. 
Production of the tissue microarrays has been 
described previously [11, 12]. Immunohis- 
tochemical detection of KLK5 was performed 
as described [4]. In short, dewaxed and rehy-
drated tissue microarray sections were treated 
for antigen retrieval by pressure cooking (4 min, 
120°C, 0.1 M citrate buffer, pH 6.0). After 
quenching endogenous peroxidase activity with 
a commercial blocking solution (#K5361, 
DAKO, Hamburg, Germany; 5 min, room tem-
perature), the sections were reacted overnight 
at 4°C with goat polyclonal antibody AF1108 
directed to KLK5 (#1108-SE; R&D Systems, 
Minneapolis, MN; 2 µg/ml) in the presence of 
antibody diluent #S2022 (DAKO). AF1108 was 
demonstrated to not cross-react with any of the 
other KLKs [4]. Interaction of antibody AF1108 
with the KLK5 target protein was visualized by 
use of the EnVision protocol (DAKO). Nuclei 
were counterstained with Mayer’s acid 
hematoxylin.
Quantification of KLK5 immunostaining
For evaluation of observer-assisted analysis of 
KLK5 tissue localization and immunostaining 
intensity, a quantitative score based on stain-
ing intensity and percentage of positive cells 
was applied. KLK5 staining intensity was classi-
fied on a scale of 0 to 3 (0: no staining; 1: weak 
staining; 2: moderate staining; 3: strong stain-
ing). The percentage of positively stained cells 
was scored by cell count on a scale of 0 to 4 (0: 
0%; 1: 1-10%; 2: 11-50%; 3: 51-80%; 4: > 80%) 
[13]. A final immunoreactivity score was creat-
ed by multiplication of the intensity score val-
ues with the cell positivity score values, sepa-
rately for the tumor cells (KLK5-Tc) and the stro-
mal cells (KLK5-Sc), respectively. In addition, 
an overall score was created by summing up 
the KLK5-Tc with the KLK5-Sc score values 
(KLK5-Tc+Sc). 
Preparation of tumor tissue extracts and quan-
tification of KLK5 antigen levels by ELISA
Tissue extracts from fresh-frozen primary 
tumor tissues of ovarian cancer patients were 
prepared as described previously [14]. The anti-
gen content of KLK5 in tumor tissue extracts 
(expressed as ng per mg of protein) was quanti-
fied following the protocol of Dorn and co-work-
ers [4] using a highly sensitive and specific in-
house sandwich-type enzyme immunoassay 
(ELISA) [15]. Lower and upper detection limits 
of this assay are 0.1 and 25 ng/ml, respective-
ly. No cross-reactivity of the KLK5 ELISA with 
any of the other member of the KLK family was 
observed. Protein content in tumor tissue 
extracts was determined by use of the BCA 
method (Pierce, Rockford, IL, USA).
Statistical analyses 
The strengths of the associations between con-
tinuous variables of tumor biological markers 
were calculated using Spearman rank correla-
tion (rs). The relationship of biological marker 
expression levels (grouped according to the 
median) with clinical and histomorphological 
parameters was evaluated using the Chi2-test. 
For survival analyses, overall survival (OS) and 
progression-free survival (PFS) of ovarian can-
cer patients were used as follow-up end points. 
Association of KLK5 and the clinical and histo-
morphological factors with OS and PFS was cal-
culated by Cox univariate and multivariable pro-
portional hazards regression models and 
expressed as hazard ratio (HR) and its 95% 
confidence interval (95% CI). The multivariable 
Cox regression model was adjusted for estab-
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lished ovarian cancer factors such as age, 
nuclear grade, presence of residual tumor 
mass, and ascitic fluid volume. Survival curves 
were plotted according to Kaplan-Meier, using 
log-rank tests to test for differences. All calcu-
lations were performed using the StatView 5.0 
statistical package (SAS Institute, Cary, NC, 
USA). P-values ≤ 0.05 were considered statisti-
cally significant. 
Results
Relationship between KLK5 expression levels 
in ovarian cancer tissue 
In the present retrospective study, we analyzed 
the clinical impact of KLK5 expression in tumor 
tissue by IHC and by ELISA, respectively, in 
patients with primary ovarian cancer (n = 95), 
encompassing advanced tumor stages (FIGO 
III/IV). IHC was performed on formalin-fixed, 
paraffin-embedded tumor tissue microarrays 
employing a KLK5-specific antibody, AF1108, 
following a previously established staining pro-
tocol [4]. Both stromal and tumor cells express 
KLK5 in ovarian cancer tissue (Figure 1), there-
fore, we individually evaluated the expression 
pattern in these cell types applying a score 
based on staining intensity and percentage of 
positively stained cells [13]. KLK5 expression 
was higher in tumor cells (Tc) compared to stro-
mal cells (Sc): the mean score value of KLK5-Tc 
was 5.7 (range 0 to 12), that of KLK5-Sc 1.2 
(range 0 to 9). The frequency of score values 
greater than zero was much higher for tumor 
cells (85, versus 7 negative) compared to stro-
mal cells (32, versus 58 negative). The antigen 
content of KLK5 was quantified in tumor 
extracts of fresh-frozen tissue by ELISA. The 
mean KLK5-ELISA (KLK5-E) value was 2.3 ng/
mg protein (range 0 to 30.9 ng/mg). 
Although statistically significant, the correlation 
between KLK5-Tc and KLK5-Sc was rather low 
(rs = 0.34, P < 0.05). No statistically significant 
correlation was observed between KLK5-ELISA 
values and KLK5-Tc or KLK5-Tc+Sc values; for 
the correlation of KLK5-E with KLK5-Sc, only a 
very weak correlation was found (rs = 0.22, P < 
0.05).
In the skin, KLK5 is coexpressed with KLK7 and 
very likely acts as the activator of KLK7 in des-
quamation. In a recent study, we analyzed the 
Figure 1. KLK5 immunoexpression in tumor tissue of ovarian cancer specimens. Tissue sections were stained with 
the goat polyclonal antibody AF1108 directed to KLK5 using the EnVision system (DAKO). Micrographs (A-D) illus-
trate representative core punches corresponding to high (+) or low (-) KLK5 immunoexpression in tumor cells (Tc) 
and stromal cells (Sc), respectively. 
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clinical value of KLK7 protein expression in 
ovarian cancer in an overlapping patient cohort 
[12] and, thus, were able to examine whether 
there is coordinate expression of both proteas-
es in ovarian cancer tissue as well. In fact, the 
KLK5 and KLK7 antigen levels determined by 
ELISA show a moderate correlation (KLK5-E vs. 
KLK7-E: rs = 0.55, P < 0.001). By IHC, KLK5-Sc 
values were found to reasonably correlate with 
KLK7-Sc as well (KLK5-Sc vs. KLK7-Sc: rs = 
0.42, P < 0.001), whereas no correlation 
between KLK5-Tc and KLK7-Tc values and only 
a weak correlation between KLK5-Tc+Sc and 
KLK7-Tc+Sc (rs = 0.24, P < 0.05) was seen.
Table 1 summarizes the association between 
clinical and histopathological patient charac-
teristics and KLK5 expression, either assessed 
by IHC or by ELISA. KLK5-E antigen levels were 
found to be significantly elevated in patients 
with advanced age and high nuclear grade (G3) 
versus low nuclear grade (G1/G2). Otherwise, 
no significant associations were observed for 
KLK5-Tc, KLK5-Sc, KLK5-Tc+Sc, or KLK5-E 
with nuclear grade, residual tumor or ascitic 
fluid volume.
Association of clinical and histomorphological 
parameters and KLK5 expression with pa-
tients’ survival
Association of relevant clinicopathological 
parameters and KLK5 protein expression lev-
els with OS and PFS, respectively, is presented 
in Tables 2 and 3. The clinicopathological vari-
ables age, residual tumor mass, and ascitic 
fluid volume are univariate predictors for both 
OS and PFS in the ovarian cancer cohort, nucle-
Table 2. Univariate Cox regression analysis of clinical outcome in advanced ovarian cancer patients 
FIGO III/IV with respect to clinicopathological parameters and KLK5 tumor tissue expression
Factor No. of cases Overall survival Progression-free survival
HR (95% CI)a P HR (95% CI)a P
Total number 95
Age
    ≤ 60 years 56 1
    > 60 years 39 2.01 (1.27-3.18) 0.003 1.76 (1.07-2.89) 0.026
Nuclear grade
    G1 + G2 27 1 1
    G3 68 1.59 (0.95-2.66) 0.077 1.22 (0.71-2.10) 0.475
Residual tumor mass
    0 mm 39 1 1
    > 0 mm 53 4.09 (2.44-6.85) < 0.001 3.40 (1.98-5.84) < 0.001
Ascitic fluid volume
    < 500 ml 53 1 1
    ≥ 500 ml 40 3.12 (1.96-4.99) < 0.001 2.59 (1.55-4.31) 0.003
KLK5-Tcb
    Low 58 1 1
    High 34 0.98 (0.61-1.57) 0.932 1.01 (0.61-1.69) 0.956
KLK5-Scb
    Low 58 1 1
    High 32 0.60 (0.32-0.99) 0.046 0.54 (0.31-0.95) 0.032
KLK5-Tc+Scb
    Low 48 1 1
    High 42 0.86 (0.54-1.36) 0.508 0.86 (0.52-1.43) 0.560
KLK5-Eb
    Low 48 1 1
    High 47 0.89 (0.56-1.39) 0.599 0.89 (0.55-1.46) 0.653
aHR: hazard ratio (95% confidence interval) of univariate Cox regression analysis. bDichotomized into high and low levels by 
median.
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ar grade G3 tumors compared to G1/2 tumors 
show a trend for poor patient survival (Table 2). 
Strikingly, elevated expression levels of KLK5 
in stromal cells, as detected by IHC, are signifi-
cantly linked with both longer OS (HR = 0.6, 
95% CI = 0.32-0.99, P = 0.046) and PFS (HR = 
0.54, 95% CI = 0.31-0.95, P = 0.032). These 
findings were confirmed by Kaplan-Meier esti-
mation: the association of KLK5-Sc levels with 
OS and PFS is visualized by the respective sur-
vival curves (Figure 2). By univariate Cox regres-
sion analysis, the tumor cell-derived score, 
KLK5-Tc, the combined overall score, KLK5-
Sc+Tc, as well as the KLK5-E values were not 
associated with patients’ outcome (Table 2). 
Since dichotomization of the tumor and stromal 
cell scores by the median leads to group sizes 
close to tertials (KLK5-Tc: median = 6.0, low: n 
= 58; high: n = 34; KLK5-Sc: median = 0, low: n 
= 58; high: n = 32), we grouped the ELISA val-
ues by tertials as well (KLK5-E: low = 62; high = 
33) and performed univariate Cox regression 
analysis. Still, no association with patients’ out-
come was observed.
In multivariable analysis, residual tumor mass 
but not the ascitic fluid volume remained signifi-
cantly associated with both OS and PFS (Table 
3). Additionally, KLK5-Sc expression was found 
to be statistically significant for PFS: ovarian 
cancer patients with elevated KLK5-Sc levels 
had an about two-fold lower risk of disease 
recurrence with an HR of 0.53 (95% CI = 0.29-
0.96, P = 0.037) as compared to patients with 
low KLK5-Sc levels (Table 3). Concerning OS, a 
trend towards statistical significance was 
observed for KLK5-Sc (HR: 0.62 (95% CI = 0.37-
1.05, P = 0.077).
Discussion
In previous studies, KLK5, a member of the 
kallikrein-related peptidase family, was pro-
Table 3. Multivariable Cox regression analysis of clinical outcome in advanced ovarian cancer pa-
tients FIGO III/IV with respect to clinicopathological parameters and KLK5 tumor tissue expression
Factor No. of cases Overall survival Progression-free survival
HR (95% CI)a P HR (95% CI)a P
Total number 90
Nuclear grade
    G1 + G2 26 1 1
    G3 64 1.23 (0.72-2.10) 0.457 0.87 (0.49-1.56) 0.644
Residual tumor mass
    0 mm 39 1 1
    > 0 mm 51 3.29 (1.69-6.41) < 0.001 3.09 (1.57-6.07) 0.001
Ascitic fluid volume
    < 500 ml 53 1 1
    ≥ 500 ml 37 1.30 (0.71-2.39) 0.393 1.25 (0.66-2.37) 0.485
KLK5-Tcb
    Low 57 1 1
    High 30 0.98 (0.58-1.63) 0.929 0.90 (0.52-1.54) 0.699
KLK5-Scb
    Low 54 1 1
    High 31 0.62 (0.37-1.05) 0.077 0.53 (0.29-0.96) 0.037
KLK5-Tc+Scb
    Low 47 1 1
    High 38 0.80 (0.49-1.31) 0.376 0.78 (0.46-1.32) 0.358
KLK5-Eb
    Low 45 1 1
    High 45 0.96 (0.59-1.58) 0.879 1.03 (0.61-1.75) 0.915
aHR: hazard ratio (95% confidence interval) of multivariable Cox regression analysis. Biological markers were added separately 
to the base model of clinical parameters: nuclear grade, residual tumor mass, and ascitic fluid volume. bDichotomized into high 
and low levels by median.
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posed as a valuable biomarker to predict poor 
clinical outcome of ovarian cancer patients. In 
the majority of ovarian cancer patients, KLK5 is 
present in their blood serum, in contrast to the 
blood serum of healthy women [4]. KLK5 may 
contribute additive value over CA125 as diag-
nostic biomarker in ovarian cancer [16]. Also, 
the initial KLK5 serum level and its decline dur-
ing chemotherapy is an indicator for the 
response of ovarian cancer patients to cancer 
therapy [17, 18]. 
In ovarian cancer tumor tissue, higher KLK5 
levels were found to be associated with an inva-
sive (as compared to tumors with low-malignant 
potential) and more aggressive cancer pheno-
type connected with poor patient outcome, at 
both the mRNA and the protein level [5, 6]. The 
clinical observation, that KLK5 may be associ-
ated with the malignant phenotype of ovarian 
cancer has been further supported by experi-
mental tumor models in mice [19, 20]: overex-
pression of KLK5 in tumor cells, among other 
KLKs, resulted in an increase of tumor load and 
intra-peritoneal spread as compared to the 
control group.
In the present retrospective study, we analyzed 
a cohort of 95 patients FIGO stage III/IV suffer-
ing from advanced primary ovarian cancer, 
treated with platinum-based chemotherapy. 
KLK5 protein expression was determined by 
IHC on a collection of primary tumor tissue 
microarrays, and by ELISA by assessing corre-
sponding tumor tissue extracts. The impact of 
KLK5 protein expression on clinical outcome 
was evaluated by univariate and multivariable 
analysis. In IHC, we observed that both stromal 
and tumor cells express KLK5 in ovarian can-
cer tissue, with less negative cases and higher 
KLK5 levels in tumor cells. KLK5 expression in 
tumor cells correlated only weakly with that in 
stromal cells and not with KLK5 antigen levels 
as assessed by ELISA. 
Recently, we determined KLK7 protein expres-
sion levels in an overlapping cohort of ovarian 
cancer patients by IHC and ELISA [12]. 
Concordant with the results for KLK5, KLK7 
immunoscores in tumor cells showed less neg-
ative cases and higher KLK7 expression levels 
than KLK7 expressed in stromal cells. For both 
KLK5 and KLK7, we observed a weak but sta-
tistically significant correlation between their 
immunoscores determined in tumor cells and 
stromal cells, respectively. In contrast to KLK7, 
however, there was no significant correlation of 
KLK5 expression determined by IHC with KLK5 
levels determined by ELISA, apart from a weak, 
but significant, correlation between KLK5-E 
and KLK5-Sc values.
In the healthy skin, both KLK5 and KLK7 are 
highly expressed and may be part of a proteo-
lytic cascade [9]. Interestingly, in ovarian can-
cer, KLK5 and KLK7 are overexpressed as com-
pared to normal or benign ovarian tissue [10]. 
Using the previous data for KLK7 [12] and the 
Figure 2. Probability of overall survival and progression-free survival of advanced ovarian cancer patients FIGO III/
IV stratified by stromal cell-associated KLK5 expression levels in primary tumor tissues. Patients with positive KLK5 
immunostaining of stromal cells in the tumor tissue (KLK5-Sc, n = 32) show significantly better overall survival 
(Kaplan-Meier analysis, P = 0.042) (A) and progression-free survival (P = 0.027) (B) than the group of patients with 
no detectable KLK5-Sc staining (n = 58).
KLK5 in ovarian cancer tissue
68 Am J Cancer Res 2016;6(1):61-70
data for KLK5 (from the present study), we 
examined whether KLK5 and KLK7 are co-
expressed in ovarian tumor tissue. By IHC, a 
significant, moderate positive correlation was 
found regarding stromal cell expression and 
the combined score, but not for tumor cells. 
KLK5 and KLK7 antigen determined by ELISA 
showed a significant medium strong corre- 
lation. 
Not surprisingly, the traditional clinical param-
eters age, residual tumor mass, and ascitic 
fluid volume are correlated with clinical out-
come in this cohort of FIGO III/IV ovarian cancer 
patients. IHC expression levels of KLK5-Tc and 
KLK5-Tc+Sc as well as KLK5-E levels were not 
related to patients’ outcome. Strikingly, howev-
er, high KLK5-Sc expression revealed KLK5 as 
a favorable biomarker for PFS and OS. Yet, this 
finding is not in line with earlier studies where 
KLK5 expression was shown to be associated 
with poor clinical outcome [5, 6]. It should, 
however, be pointed out that these studies 
used other methods for the assessment of 
KLK5 expression, either RT-PCR or ELISA. 
Furthermore, these studies included also early 
FIGO stage I/II patients in addition to advanced 
cancer stages. It, thus, is certainly of interest to 
explore the clinical relevance of stromal cell-
associated KLK5 expression in early FIGO 
stage I/II patients in future studies as well. 
Interestingly, in the earlier mentioned study of 
KLK7 expression in ovarian cancer tissue, we 
also found elevated KLK7 protein levels in 
tumor tissue extracts to be associated with 
longer PFS and OS [12]. In other types of can-
cers, such as breast cancer and oral squamous 
cell carcinoma [21, 22], concurrent downregu-
lation of KLK5 and KLK7 have been reported 
indicating that reduction of the expression lev-
els of these KLKs support tumorigenesis in 
these cancer types. In fact, a recent experimen-
tal study suggested that KLK5 may suppress 
breast cancer by inhibiting epithelial-to-mesen-
chymal transition and by modulating the 
mevalonate pathway [23].
The patient cohort analyzed in the present 
study encompasses advanced ovarian cancer 
stages (FIGO III/IV) only, characterized by very 
poor clinical outcome owing to the relatively 
unsatisfying operation results (optimally 
debulking rate of 41%) leading to high disease 
recurrence levels and short OS. It is tempting to 
speculate that KLK5 may play different roles in 
stromal and tumor cells due to differing sub-
strate repertoires in the vicinity of the respec-
tive cell type. Therefore, high expression of 
KLK5 in stromal cells but not in tumor cells may 
lead to a less aggressive tumor phenotype 
and/or better response to chemotherapy. 
Previously, we have examined tumor tissue 
localization and protein expression levels of 
another member of the KLK family, KLK6, in 
ovarian cancer by IHC [11]. Similar to the pre-
sent study, we observed that stromal cell but 
not tumor cell-associated expression, is related 
to patients’ outcome. In case of KLK6, elevated 
tissue expression levels were associated with 
reduced PFS and OS of ovarian cancer patients 
[11]. Thus, the results obtained with KLK5 and 
KLK6 point to an important contribution of 
tumor tissue-associated stromal cell proteases 
to tumorigenicity. 
In conclusion, in this study, we examined KLK5 
protein expression in the clinically important 
ovarian cancer subgroup stage FIGO III/IV, 
using IHC (tissue microarrays) and ELISA (tumor 
tissue extracts). Our results indicate that low 
KLK5 expression in stromal cells is related to 
an unfavorable clinical outcome of patients 
with advanced ovarian cancer by predicting 
shorter PFS and OS due to minor therapy 
response. Those patients could benefit from 
alternative therapy approaches and/or should 
be monitored more closely after primary thera-
py for recurrent disease. 
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